Cancer Treatment Reviews
Volume 36, Issue 6 , Pages 468-476 , October 2010

The cost-effectiveness of particle therapy in non-small cell lung cancer: Exploring decision uncertainty and areas for future research

  • Janneke P.C. Grutters

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre, P.O. Box 1588, 6201 BN Maastricht, The Netherlands
    • Department of Health Organization, Policy and Economics, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Department of Health Organization, Policy and Economics, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands. Tel.: +31 433881973; fax: +31 433670960.
    • ,
  • Madelon Pijls-Johannesma

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre, P.O. Box 1588, 6201 BN Maastricht, The Netherlands
    • Tel.: +31 884455666; fax: +31 884455667.
    • ,
  • Dirk De Ruysscher

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre, P.O. Box 1588, 6201 BN Maastricht, The Netherlands
    • Tel.: +31 884455666; fax: +31 884455667.
    • ,
  • Andrea Peeters

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre, P.O. Box 1588, 6201 BN Maastricht, The Netherlands
    • Tel.: +31 884455666; fax: +31 884455667.
    • ,
  • Stefan Reimoser

      Affiliations

    • Turner and Townsend GmbH, St.-Martin-Straße 76, 81541 München, Germany
    • Tel.: +49 89 636 86928; fax: +49 89 636 81973.
    • ,
  • Johan L. Severens

      Affiliations

    • Department of Health Organization, Policy and Economics, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
    • Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
    • Tel.: +31 433882907; fax: +31 433670960.
    • ,
  • Philippe Lambin

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre, P.O. Box 1588, 6201 BN Maastricht, The Netherlands
    • These authors contributed equally to this work.
    • Tel.: +31 884455666; fax: +31 884455667.
    • ,
  • Manuela A. Joore

      Affiliations

    • Department of Health Organization, Policy and Economics, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
    • Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
    • These authors contributed equally to this work.
    • Tel.: +31 43 3875434; fax: +31 43 3874419.

Received 11 January 2010 ,Revised 17 February 2010 ,Accepted 23 February 2010.

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249
  2. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3:819–831
  3. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27:3868–3874
  4. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed.. Oxford: Oxford University Press; 2005;
  5. Grutters JPC, Kessels AGH, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for stage I to III non-small cell lung cancer: a meta-analysis. Radiother Oncol, in press. doi:10.1016/j.radonc.2009.08.003.
  6. Pijls-Johannesma M, Grutters JP, Lambin P, Ruysscher DD. Particle therapy in lung cancer: where do we stand?. Cancer Treat Rev. 2008;
  7. Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health. 2003;6:9–17
  8. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006;
  9. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet. 2002;360:711–715
  10. Glatstein E, Glick J, Kaiser L, Hahn SM. Should randomized clinical trials be required for proton radiotherapy? An alternative view. J Clin Oncol. 2008;26:2438–2439
  11. Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy?. J Clin Oncol. 2008;26:175–176
  12. Anonymous . Introducing new treatments, technologies into the clinic. J Clin Oncol. 2008;26:2425
  13. Glimelius B, Montelius A. Proton beam therapy – do we need the randomised trials and can we do them?. Radiother Oncol. 2007;83:105–109
  14. Goitein M. Magical protons?. Int J Radiat Oncol Biol Phys. 2008;70:654–656
  15. Lewis BE. On equipoise and emerging technologies. J Clin Oncol. 2008;26:2590
  16. Macbeth FR, Williams MV. Proton therapy should be tested in randomized trials. J Clin Oncol. 2008;26:2590-a-1
  17. Morgan JP. A patient’s perspective on randomized clinical trials for proton radiotherapy. J Clin Oncol. 2008;26:2592
  18. Suit H, Kooy H, Trofimov A, et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted?. No Radiother Oncol. 2008;86:148–153
  19. Tepper JE. Protons and parachutes. J Clin Oncol. 2008;26:2436–2437
  20. Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE). <http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf>; 2006 [accessed 03.02.2010].
  21. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65:1–7
  22. Paganetti H. The impact of protons on the incidence of second malignancies in radiotherapy by Eric J. Hall (Supp.31–34; 2007). Technol Cancer Res Treat, 2007;6:661–662.
  23. Paganetti H, Bortfeld T, Delaney TF. Neutron dose in proton radiation therapy: in regard to Eric J. Hall (Int J Radiat Oncol Biol Phys, 2006;65:1–7). Int J Radiat Oncol Biol Phys, 2006;66:1594–1595 [author reply 5].
  24. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2:S94–S100
  25. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51:666–670
  26. Miyamoto T, Baba M, Sugane T, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol. 2007;2:916–926
  27. Miyamoto T, Baba M, Yamamoto N, et al. Curative treatment of stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys. 2007;67:750–758
  28. The EuroQol Group . EuroQol – a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208
  29. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–1108
  30. Health Care Insurance Board . Guidelines for pharmaco-economic research (in Dutch). Diemen: Health Care Insurance Board; 2006;
  31. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Manual for costing research (in Dutch). Amstelveen: College voor zorgverzekeringen; 2004;
  32. Peeters A, Grutters JPC, Pijls-Johannesma M, et al. How costly is radiotherapy with particles? Cost analysis of external beam radiotherapy with carbon ions, protons and photons. Radiother Oncol, in press. doi:10.1016/j.radonc.2009.12.002.
  33. Council for Public Health and Health Care . Sensible and sustainable care (in Dutch). Zoetermeer: Council for Public Health and Health Care; 2006;
  34. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994;3:309–319
  35. Hoyer M. Improved accuracy and outcome in radiotherapy of lung cancer. Radiother Oncol. 2008;87:1–2
  36. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 1996;5:513–524
  37. Dutch Cancer Registry. <http://www.ikcnet.nl/index.php>; 2010 [accessed 12.02.2010].
  38. Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics. 2004;22:857–876
  39. Wild C, Langer T. Emerging health technologies: informing and supporting health policy early. Health Policy. 2008;87:160–171
  40. Willan A, Kowgier M. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. Clin Trials. 2008;5:289–300
  41. Cox JD, Chang J, Liao Z, et al. Acute esophageal reactions from proton beam therapy, concurrent chemotherapy for non-small cell lung cancer (NSCLC): reduction in incidence, severity despite higher doses. J Thorac Oncol. 2007;2:S449
  42. Komaki R, Sejpal SV, Wei X, et al. Reduction of bone marrow suppression for patients with stage III NSCLC treated by proton and chemotherapy compared with IMRT and chemotherapy. In: Conference of the particle therapy co-operative group, vol. 47. Jacksonville, Florida; 2008. p. 14.
  43. Sejpal SV, Komaki R, Wei X, et al. Does proton beam radiotherapy (PBT) reduce treatment related pneumonitis (TRP) compared to intensity modulated related radiation therapy (IMRT) in patients with locally advanced non-small cell lung cancer (NSCLC) treated with concurrent chemotherapy? In: Conference of the particle therapy co-operative group, vol. 47. Jacksonville, Florida; 2008. p. 22.
  44. Collins R, Fenwick E, Trowman R, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess. 2007;11:p. iii–iv, xv–xviii, 1–179
  45. Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N. Surveillance of Barrett’s oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess. 2006;10:p. 1–142, iii–iv
  46. Hassan C, Pickhardt PJ, Di Giulio E, Hunink MG, Zullo A, Nardelli BB. Value-of-information analysis to guide future research in the management of the colorectal malignant polyp. Dis Colon Rectum. 2010;53:135–142
  47. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health. 2009;12:20–27
  48. Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ. 2007;16:195–209

PII: S0305-7372(10)00039-3

doi: 10.1016/j.ctrv.2010.02.018

Cancer Treatment Reviews
Volume 36, Issue 6 , Pages 468-476 , October 2010

Article Tools

* Image Usage & Resolution